48 results about "Opioid addiction" patented technology

A short treatment with noribogaine shows promise for treating drug dependency. Many opioid addicts are treated with methadone. Giving noribogaine to mammal concurrently being administered methadone surprisingly exacerbates methadone's negative side-effects, and increases the risk of death. Therefore, prior to noribogaine treatment, a patient on methadone therapy undergoes a period of methadone abstinence to wash out the methadone. Surprisingly, noribogaine does not react negatively to morphine. According to the invention, methadone regimen is replaced with morphine prior to noribogaine treatment.

The present invention relates to application of N(6)-(2-hydroxyethyl)-adenosine (HEA) and its derivatives as an adenosine A₁ receptor agonist in preparation of drug or food, the HEA and its derivatives are used in treatment of diseases relating to adenosine receptor regulator, such as insomnia, pain, convulsion, apoplexia, Parkinson's disease, opioid drug addiction and kidney ischemia reperfusion injury etc. The present invention provides a new method for treatment of the diseases relating to nervous system and kidney.

The invention relates to an application of Lorcaserin hydrochloride in preparation of a medicine for inhibiting opioid addiction and withdrawal syndrome. The Lorcaserin hydrochloride is approved to be a weight-reducing aid by the America Food and Drug Administration (FDA) in 2012. The Lorcaserin hydrochloride is a 5-hydroxytryptamine 5-HT2C receptor stimulant with high selectivity. The latest research of the invention finds that the Lorcaserin hydrochloride (0.5-1.0mg.kg<-1>) greatly reduces the naloxone-urged horizontal motion distance and speed of a morphine dependent mice and the withdrawal syndrome of the mice. It is found in the invention for the first time that the Lorcaserin hydrochloride can be applied clinically for rescuing and treating addiction and withdrawal syndrome generated by morphine and other opiates.

The present invention pertains to novel uses of endomorphine-1 peptide, analogs, and salts thereof for therapy of children, patients currently suffering from drug addiction, patients prone to opioid addiction, and patients with chemo-induced pain.

Compounds for treating abuse of nicotinic receptor agonists, addiction to psychostimulant drugs, addiction to opiates, addiction to alcohol, addiction to tobacco products, addiction to nicotine, schizophrenia and related diseases, depression and related conditions, Alzheimer's disease, Parkinson's disease, irritable bowel syndrome, and colitis. The compounds competitively inhibit central nervous system acting nicotinic receptor agonists and act at the putative α3β2* and α4β2 neuronal nicotinic receptors in the central nervous system.

The present disclosure relates to the transdermal administration of psychedelics, such as psilocybin, psilocin, lysergic acid diethylamine (LSD), and/or ibogaine, and derivatives of these compounds, for the treatment and/or prevention and/or control of severe depression (treatment resistant), major depressive disorder, obsessive-compulsive disorder, quitting smoking, alcohol addiction, cocaine addiction, opioid addiction, anxiety (stress), adult ADHD, cluster headaches, and cancer related or other end-of-life psychological distress.

The present invention provides a compound having the structure:

or a pharmaceutically acceptable salt or ester thereof, and a method of treating a subject afflicted with a pain, a depressive disorder, a mood disorder, an anxiety disorder, borderline personality disorder, opioid addiction, or opioid withdrawal symptoms by administering the compound to the subject.

The invention relates to a Chinese herbal medicine composition used for detoxification treatment. The material composition for preparing the effective components of the composition is listed as follows according to weight shares: rhizoma corydalis 100 to 10000 shares, greater celandine 200 to 20000 shares, radix stephaniae cepharanthae 200 to 20000 shares, radix stephaniae tetrandrae 100 to 10000 shares, hyoscyamus niger 3 to 300 shares, angelica sinensis 75 to 7500 shares, tuber fleeceflower 10 to 1000 shares, medlar 20 to 2000 shares, ginseng 8 to 800 shares, albizzia peel 100 to 10000 shares, spine data seed 40 to 4000 shares, radix glycyrrhizae 75 to 7500 shares. The Chinese herbal medicine composition has the functions of antispasmodic, taking away the pain, cooling blood, detoxifying, relieving cough and eliminating phlegm, diuresis, soothing the nerves, nourishing liver and kidney, nourishing yin and producing energy, reinforcing spleen and strengthening lung, reinforcing qi and nourishing blood, soothing the nerves and promoting intelligence, soothing the nerves and fixing the sensorium and supporting the healthy energy, and can be used for acute withdrawal of opioid addiction.

Extended release of sufentanil is provided by implanting a device containing sufentanil into a mammal or human being. The device may include a solid biocompatible polymer matrix, and sufentanil may be encapsulated within the polymer matrix. The polymer matrix comprises a plurality of pores configured to allow contact between the sufentanil and a physiological fluid of a mammal into which the device is implanted to thereby release sufentanil in vivo from the device into the mammal. The devices may be used to treat opioid addiction or pain.

A method of averting opioid addiction in a patient is disclosed. The method can be applied to a patient suffering from moderate to severe low back pain (LBP). The method comprises: diagnosing the patient as suffering from low back; administering to the patient a pharmaceutical composition comprising a therapeutically effective amount of an antibody that binds specifically to nerve growth factor (NGF) or an antigen binding fragment thereof; and avoiding administration of an opioid to the patient, and thereby relieving pain, and averting opioid addiction in a patient.

The invention belongs to the field of chemical pharmacy and relates to a 7beta-methyl-tetralone derivative shown in a general formula (I) and a preparation method thereof. According to the compound shown in the general formula (I), with thebaine as a raw material, through related conversion methods such as N-demethylation, N-acylation, a Diels-Alder reaction and reduction, oxidation and Grignard reactions, the compound is synthesized. The compound shown in the general formula (I) belongs to an opioid receptor ligand, a radioactive receptor ligand combination experiment is adopted, the affinityand selectivity of the ligand to three subtypes of an opioid receptor are measured, and a [35S]GTPgammaS combination experiment is adopted for measuring the excitement inhibitory activity of the ligand; it is proved through a result that the compound has the functions of alleviating pain, resisting depression, withdrawing opioid addiction, relieving itching and the like and can be applied to preparation of an opioid receptor treatment medicine and applied to clinical analgesia or depression resistance or opioid addiction withdrawal treatment or itching relieving treatment.

The invention described herein solves the challenges encountered in providing a safe, efficacious, and satisfactory option for the treatment of opioid addiction. Methods and devices of the invention allow a subject to receive an implantable formulation comprising an opioid receptor ligand, buprenorphine, or a metabolite thereof as a treatment for opioid addiction. The invention preempts several difficulties encountered with conventional methods for the treatment of opioid addiction, and by doing so the invention improves treatment adherence, compliance, subject satisfaction, and overall success rate.

The invention relates to a preparation method of a compound with a general formula (I) or pharmaceutically acceptable salts thereof, and relates to an application of the derivatives in the field of opioid receptor treatment, and an application of the derivatives in preparation of medicines for treating pain, depression, opioid addiction and pruritus. The treatment of pains comprise treatment or relief of pains, chronic pains, neuropathic pains and cancer pains during an operation; the pruritus comprises intractable pruritus accompanied by serious diseases such as uremia, diabetic nephropathy, chronic liver diseases and malignant tumors. Formula (I) as shown in the specification,.

The invention discloses application of hederagenin in preparation of drug rehabilitation drugs, the hederagenin has no addiction and toxic and side effects, and has very good curative effects in a morphine addiction formation period, a fading period after the use of morphine is stopped, an abstinence delay period and a relapse period when the hederagenin is exposed to a morphine condition again. Hederagenin is a compound monomer derived from a traditional Chinese medicine astragalus membranaceus, can be sold in the market instead of a controlled drug, and can act on a classical pathway of opioid drug addiction; in addition, through further mechanism research on the traditional Chinese medicine monomer provided by the invention, the curative effect is determined, the price is moderate, and the traditional Chinese medicine monomer has a good commercial prospect.

The invention provides methods and compositions for treating opioid addiction by identifying patients at high risk of failing opioid agonist replacement therapy before therapy has begun. Related compositions, in the form of kits, systems, and computer-readable media are also provided.

A substance with sedative effect comprises a therapeutically effective amount of a gamma-pyrone such as comenic acid, meconic acid, chelidonic acid, and alike in a pharmaceutically acceptable carrier. When administered at a daily dosage of between 5 and 200 mg of active ingredient per kilogram of a body weight of a patient, the substance can be used to treat various neurotic disorders such as insomnia, anxiety, neurosis, depression as well as withdrawal symptoms for drug addiction patients, especially for patients addicted to opioid-based drugs. The substance can be delivered in a number of ways of systemic administration of a pharmaceutical agent including oral, parenteral, transdermal, and transmucosal administration. For drug addicted patients, the preferred method of administration involves a subcutaneous implant providing a continuous release of an active ingredient at an effective daily rate over the entire treatment period ranging from 5 to 30 days, and preferably from 13 to 20 days.

The invention provides a compound of formula I and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the formula I compounds, as well as methods of using such as therapeutic agents for the treatment of pain-related disorders and diseases and in combination with other therapeutic agents.

The invention belongs to the field of pharmacy, and relates to a 7alpha-methyl fused ring morphine compound with a formula I and a formula II as well as a preparation method and an application of the 7alpha-methyl fused ring morphine compound. The compounds are prepared through a reaction of thebaine and a substituted styrene reagent and through a series of conversion methods, have opioid receptor binding activity, and multiple compounds including SLL-604, SLL-627 and SLL-631 are selective kappa receptor ligands or mu/kappa dual ligands. The method can be applied to research and development in the treatment fields of pain easing, depression resisting, opioid drug addiction withdrawal, itching relieving and the like.

The present invention provides a method of treating a respiratory illness in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound comprising a reaction product of a reaction mixture comprising: a) N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide or a derivative thereof; and b) dimethyl sulfoxide. Also provided are methods of alleviating opioid addiction while suppressing withdrawal symptoms and alleviating inflammation and visceral pain with minimal risk of addiction in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound described above.

The invention discloses a traditional Chinese medicine composition for abandoning drug habits and a preparation method thereof. The traditional Chinese medicine composition is obtained by weighing eight medicinal materials, that is, ginseng, radix astragali, flos daturae, corydalis tuber, cortex acanthopanacis, radix ophiopogonis, herba gynostemmatis pentaphylli and smallflower milkwort herb withroot, boiling the medicinal materials with water for two times, combining the filtrates, and conducting concentrating and vacuum drying. The medicinal materials in the traditional Chinese medicine composition for abandoning drug habits of the invention are all cheap and easy to obtain, can be sold in the market, are not controlled drugs, and have no toxic and side effects. The traditional Chinesemedicine composition can exert the effects of replenishing qi and nourishing yin, dispelling toxin and securing the root, and also can improve nervous system changes caused by opioids, gradually restore the normal physiological functions of the nervous system, and better prevent opioid addiction and reduce withdrawal syndromes caused by emergency withdrawal of opioids; and in addition, the traditional Chinese medicine composition provided by the invention has convenient use and low cost, can significantly reduce the economic burden of a patient, and has a good commercial prospect.